Ricardo Carvalho

How immunotherapy transformed survival in advanced melanoma

🫀 ICI myocarditis: diagnosis remains challenging 📊 Meta-analysis (29 studies, n=3568) 🔎 CMR abnormal in 63% (LGE ~65%) 📉 ↓ LVEF in 36% 🧪 ↑ troponin & BNP ⚠️ No single parameter is diagnostic 💡 Multimodal assessment is key 🔗 doi.org/10.1016/j.ejca… @OncoAlert

1/n Now published in @NatureMedicine : The phase 2 #POLAR trial of pembrolizumab + olaparib maintenance in metastatic pancreatic cancer. @CpcrMsk @MSKCancerCenter @MSK_DeptOfMed @PICIatMSK rdcu.be/e9WmJ

💉 Pegfilgrastim timing matters 📊 Phase III RCT (breast cancer) ⏱️ 72h vs 24–48h post-CT 📉 Bone pain (AUC): 6.05 vs 12.7–14.2 🔥 📉 Severe pain: 22.6% vs ~60% ⚖️ No ↑ neutropenia or FN 💡 Delaying to 72h may reduce toxicity without compromising efficacy 🔗 doi.org/10.7326/ANNALS… @OncoAlert

Surviving Sepsis Campaign 2026 guidelines just dropped. Here is the link link.springer.com/article/10.100…

Number Needed to Treat | New England Journal of Medicine - what a great editorial! nejm.org/doi/full/10.10…

1/ 🚨 New @NEJM: Perioperative enfortumab vedotin + pembrolizumab (EV+pembro) in MIBC (KEYNOTE-905) Congrats to the authors on an important randomized phase 3 trial in a tough, cisplatin-ineligible population 👏 Let’s walk through it 👇

These combinations could change the history of this deadly disease. Oncology is moving at light speed ⚡️ Hopefully, this is just the beginning

🧵 ESOPEC debate: is nCRT being underestimated? (1/2) 📉 Concerns on nCRT arm: • Low pCR (10%) vs real-world (~18%) • High distant relapse (50%) • RT technique → ↑ cardiac dose (MHD) 🔎 Potential impact on survival & systemic control 🔗 doi.org/10.1200/JCO-25… @OncoAlert

What's new in upper gastrointestinal pathology: Key updates and evolving challenges in 2026 sciencedirect.com/science/articl… #GIpath

A comprehensive overview of the molecular subtypes of Breast cancer, their clinical characteristics, and their common sites of metastasis. mdpi.com/2072-6694/14/2…

JAMA Oncology—The Year in Review, 2025 jamanetwork.com/journals/jamao…

@raicher Zero chance de fim de Bear agora. Podemos ter um falso repique agora. Mas ainda vamos buscar ~48-54k antes do fim do Bear. Lateralizamos uns meses e começa a subir novamente somente em SET-OUT/26. Pode anotar. De nada. Abs.

Não tenho certeza se já apresentei o ciclo do Bitcoin #Semanal aqui no X, mas ele é contado a cada vez que Resetamos o RSI abaixo do 30. Este é outro indício que eu tenho de que o Bear Market está chegando ao fim em breve, se é que já não chegou. O Ciclo sempre termina com um susto, portanto, EU não me surpreenderia (vocês sim) se mais um flush out acontecer até lá, mas o mais importante é que sabemos que ele está terminando. 😅 Normies em geral demoram uns 5-6 meses para a ficha cair depois do fato.

Routine Surveillance for Cancer Metastases — Does It Help or Harm Patients? | New England Journal of Medicine nejm.org/doi/full/10.10…

#ColorectalCancer incidence and mortality continue to decline in adults ≥65, decreasing by >2% per year. However, rectal cancer incidence increased 1% per year across all ages from 2019–2022, reversing decades of decline. More stats: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @OncoAlert #CRCSM

These numbers don’t tell the full story! Great summary by @GIcancerDoc on key real questions in the comments: 1. Is ctDNA ready for all? 2. Can we skip surgery after IO? 3. How much IO is good enough? 4. Role of Chemo here? #OncTwitter #gism @OncUpdates @manjuggm

PSA, Gleason, T stage—pick the WORST → final risk. Low = all low Intermediate = one problem (split) High = ANY high feature Think: 10–20 | 6–7–8 | T2 cut #MVOnco #ProstateCancer #Oncology #MedEd

NICE 2026 guideline for the diagnosis and management of kidney cancer thelancet.com/journals/lanon…

Why should tumor whole genome sequencing (WGS) be done for cancer? In real practice of medicine study of 888 patients with solid cancers, WGS directly led to clinical consequences in over 40% @NatureMedicine nature.com/articles/s4159…

Less than 2 months to @AACR! Thrilled to speak in the Major Symposium:RAS Inhibitors,Mechanisms of Resistance, & Drug Combinations. Grateful to the NextGen Stars Program for this opportunity. Looking forward to great science, connect with people & new collaborations. #AACR26